HilleVax reports Q4 EPS (78c), consensus (83c)

As of December 31, 2023 and December 31, 2022, the company had cash, cash equivalents and marketable securities totaling $303.5M and $279.4M, respectively. The increase was due to $107.8M of net proceeds received from the issuance of common stock in an underwritten public offering. “Over the past year, we made significant progress with HIL-214, our vaccine candidate for the prevention of moderate-to-severe norovirus related acute gastroenteritis. We have continued to progress the NEST-IN1 clinical trial and remain on track to report topline data by mid-2024,” said Rob Hershberg, chairman and CEO of HilleVax. “We have also made good progress on our manufacturing activities for HIL-214 in support of continued development in subsequent registrational trials for infants and older adults.”